1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Hope Medicine’s HMI-115 Shows Statistically Significant Pain Reduction in Phase 2 Endometriosis Study

08 Oct 2025
Admin
News Article

Hope Medicine’s HMI-115 Shows Statistically Significant Pain Reduction in Phase 2 Endometriosis Study

Hope Medicine Inc. (HopeMed), a clinical-stage biopharmaceutical company focused on innovative women’s health therapies, announced the successful completion of a global Phase 2 study evaluating HMI-115, a monoclonal antibody targeting the prolactin receptor, for moderate to severe endometriosis-associated pain.

The 12-week, randomized, multicenter, double-blind, placebo-controlled trial included 108 women with surgically confirmed endometriosis across the US, Poland, and China.

Key Findings

Dysmenorrhea pain reduction: Mean pain score decreased by 42%
Non-menstrual pelvic pain reduction: Mean score decreased by 52%
Normal menstrual periods: Most patients maintained regular cycles
Hormonal safety: No significant changes in sex hormones (estradiol, LH, FSH, progesterone)
Bone health: No significant changes in bone mineral density
Menopausal symptoms: None reported
Tolerability: HMI-115 was well-tolerated, with no treatment-related serious adverse events

Expert Perspectives

Lan Zhu, Director of Gynecology at Peking Union Medical College Hospital:

"HMI-115 relieved endometriosis pain in women without disturbing their sex hormones. It can potentially shift the treatment paradigm, allowing treatment without menopausal side effects or impacting fertility."

Professor Rui-Ping Xiao, Founder of Hope Medicine:

"HMI-115 is the first prolactin receptor blocker for endometriosis and the first non-hormonal treatment worldwide to clear proof-of-concept. This represents a major step forward for women’s health."

Nathan Chen, CEO of Hope Medicine:

"HMI-115 is Phase 3 ready. We are actively engaging with regulatory agencies, including the FDA and NMPA, to finalize the Phase 3 protocol and initiate global studies."

About Endometriosis

Affects approximately 190 million women worldwide, with a global market size of $200 billion
Characterized by the implantation of endometrial cells outside the uterus, causing chronic inflammation
Common symptoms: pelvic pain, dysmenorrhea, painful intercourse, infertility
Impacts quality of life, sexual health, and psychological wellbeing

About Hope Medicine

Hope Medicine Inc. is a science-driven clinical-stage biopharmaceutical company with research laboratories in Beijing, Shanghai, and Nanjing. Built on decades of research from Professor Rui-Ping Xiao’s laboratory at Peking University, HopeMed is committed to developing first-in-class medicines for major diseases and improving patients’ quality of life.